Cost estimates and economic implications of expanded ras testing in metastatic colorectal cancer

Oncologist

Volumn 20, Issue 1, 2015, Pages 14-18

  Kircher, Sheetal M ^a   Mohindra, Nisha ^a   Nimeiri, Halla ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antineoplastic agents; Colorectal neoplasms drug therapy; Drug costs; Human; KRAS protein

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CANCER INCIDENCE; CANCER THERAPY; COLORECTAL CANCER; DRUG COST; ECONOMIC ASPECT; EXON; GENE MUTATION; GENETIC SCREENING; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; METASTASIS;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84921291681     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0252     Document Type: Article

References (35)

1. de Reynies A, Boige V, Milano G et al. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 2008;26:2228–2230; author reply 2230–2231.
2. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. N Engl JMed 2009; 360:1408–1417.
3. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27: 663–671.
4. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl JMed 2008;359: 1757–1765.
5. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230–3237.
6. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–379.
7. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–1634.
8. Van Cutsem E, Siena S, Humblet Y et al. An openlabel, single-armstudyassessing safetyandefficacyof panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92–98.
9. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166–1169.
10. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101:715–721.
11. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from theMRCFOCUS trial. J Clin Oncol 2009; 27:5931–5937.
12. Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: Biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010;28:1181–1189.
13. Dahabreh IJ, Terasawa T, Castaldi PJ et al. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011;154:37–49.
14. Tougeron D, Lecomte T, Pages JC et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013;24:1267–1273.
15. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28:4697–4705.
16. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706–4713.
17. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682–4689.
18. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The ‘RASCAL II’ study. Br J Cancer 2001;85: 692–696.
19. Jimeno A, Messersmith WA, Hirsch FR et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection. J Clin Oncol 2009;27:1130–1136.
20. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705–5712.
21. GarmSpindler KL, Pallisgaard N, Rasmussen AA et al. The importance of KRAS mutations and EGF61A.G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20:879–884.
22. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369: 1023–1034.
23. Schwartzberg LS, Rivera F, Karthaus M et al. Analysis of KRAS/NRASmutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31 (suppl):3631a.
24. Fornaro L, Lonardi S, Masi G et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF)metastatic colorectal cancer patients: A phase II trialbytheGruppoOncologicoNordOvest (GONO). Ann Oncol 2013;24:2062–2067.
25. Peters M, Oliner KS, Price TJ et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32(suppl 3):LBA387a.
26. Tajpar S, Lenz HJ, Kohne CH et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treatedfirst-line with cetuximab plusFOLFOX4:New results from the OPUS study. J Clin Oncol 2014;32 (suppl 3):LBA444a.
27. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: Are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 2010; 16:5972–5980.
28. Vijayaraghavan A, Efrusy MB, Goke B et al. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. Int J Cancer 2012;131:438–445.
29. Cancer facts & figures 2012. Available at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed September 25, 2014.
30. Current procedural terminology, Fourth edition. Available at http://www.Cms.Gov/apps/ama/license.Asp?File5/clinicallabfeesched/downloads/14clab.Zip. Accessed September 25, 2014.
31. Medicare Part B drug average sales price. Available at http://www.cms.gov/medicare/medicare-feefor-service-part-b-drugs/mcrpartbdrugavgsalesprice/index.Html. Accessed December 3, 2013.
32. SEER stat fact sheets: Colon andrectumcancer. Available at http://seer.cancer.gov/statfacts/html/colorect.html. Accessed September 25, 2014.
33. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103: 117–128.
34. Oliner KS, Douillard J-Y, Siena S et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31(suppl):3511a.
35. NCCNguidelines:Coloncancer(version1.2015). Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed September 25, 2014.